Fluorine in drug design: a case study with fluoroanisoles

ChemMedChem. 2015 Apr;10(4):715-26. doi: 10.1002/cmdc.201402555. Epub 2015 Mar 6.

Abstract

Anisole and fluoroanisoles display distinct conformational preferences, as evident from a survey of their crystal structures. In addition to altering the free ligand conformation, various degrees of fluorination have a strong impact on physicochemical and pharmacokinetic properties. Analysis of anisole and fluoroanisole matched molecular pairs in the Pfizer corporate database reveals interesting trends: 1) PhOCF3 increases log D by ~1 log unit over PhOCH3 compounds; 2) PhOCF3 shows lower passive permeability despite its higher lipophilicity; and 3) PhOCF3 does not appreciably improve metabolic stability over PhOCH3 . Emerging from the investigation, difluoroanisole (PhOCF2 H) strikes a better balance of properties with noticeable advantages of log D and transcellular permeability over PhOCF3 . Synthetic assessment illustrates that the routes to access difluoroanisoles are often more straightforward than those for trifluoroanisoles. Whereas replacing PhOCH3 with PhOCF3 is a common tactic to optimize ADME properties, our analysis suggests PhOCF2 H may be a more attractive alternative, and greater exploitation of this motif is recommended.

Keywords: ADME profiles; anisoles; drug design; fluorination; metabolic stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anisoles / chemistry*
  • Anisoles / metabolism
  • Anisoles / pharmacokinetics
  • Cell Line
  • Dogs
  • Drug Design*
  • Fluorine / chemistry*
  • Fluorine / metabolism
  • Fluorine / pharmacokinetics
  • Halogenation
  • Humans
  • Ligands
  • Microsomes, Liver / metabolism
  • Permeability

Substances

  • Anisoles
  • Ligands
  • Fluorine